Study Design Checklist
Overview
Good analysis starts with good study design. This checklist ensures key design elements are addressed before analysis begins.
Research Question Formulation
PICO(T) Framework
| Component |
Question |
Example |
| Population |
Who are we studying? |
Adult ICU patients with sepsis |
| Intervention/Exposure |
What exposure or treatment? |
Early vs. late vasopressor initiation |
| Comparison |
Compared to what? |
Standard care, alternative treatment, no exposure |
| Outcome |
What are we measuring? |
28-day mortality |
| Time |
Over what period? |
Within first 24 hours of ICU admission |
Question Checklist
Cohort Definition
Inclusion Criteria
Define who enters the study:
| Criterion Type |
Examples |
| Diagnosis |
Sepsis-3 criteria, ICD codes, clinical definition |
| Setting |
ICU admission, specific unit type |
| Age |
Adults (≥18), specific range |
| Time |
Admission within study period |
| Data quality |
Required variables available |
Exclusion Criteria
Define who is removed (with justification):
| Criterion |
Justification |
| Age <18 |
Pediatric physiology differs |
| LOS <24h |
Insufficient observation time |
| Readmission |
Avoid correlated observations |
| Missing outcome |
Cannot assess endpoint |
| Prior exposure |
Clean exposure window needed |
| Comfort care only |
Different treatment goals |
Documentation Requirements
For each criterion, document:
- Exact definition (codes, thresholds, timing)
- Number excluded at each step
- Justify each exclusion
CONSORT-style flow diagram recommended.
Unit of Analysis
Options
| Unit |
When to Use |
Watch For |
| Patient |
One observation per person |
Multiple admissions → choose first, last, or random |
| Admission |
One observation per hospitalization |
Same patient multiple times → clustering |
| ICU stay |
One observation per ICU episode |
Transfers between units |
| Patient-day |
Time-varying exposures |
Autocorrelation |
Key Decision: Multiple Events per Patient
If patients can have multiple admissions/stays:
| Approach |
Pros |
Cons |
| First only |
Simple, independent |
Loses data, selection bias |
| Last only |
May capture sickest |
Selection bias |
| Random one |
Unbiased selection |
Loses data |
| All (clustered) |
Uses all data |
Must model clustering |
| Index event (defined criteria) |
Clinically meaningful |
Requires clear definition |
Time-Zero and Follow-Up
Time-Zero Definition
Time-zero is the moment when:
- Follow-up begins
- Patient becomes "at risk" for outcome
- Exposure status should be determined (or treatment assigned)
| Common Choices |
Appropriate When |
| Hospital admission |
Studying hospital-wide exposures |
| ICU admission |
ICU-specific questions |
| Diagnosis time |
Studying disease course |
| Treatment initiation |
Caution: immortal time bias if not universal |
| Fixed landmark (e.g., day 3) |
Ensuring minimum exposure time |
Follow-Up Period
- Start: Time-zero
- End: Outcome, death, discharge, loss to follow-up, or administrative censoring
- Fixed horizon: e.g., 30 days, 90 days, hospital stay
Censoring
Define what ends follow-up without outcome:
- Discharge alive
- Transfer to another facility
- End of study period
- Loss of data availability
Consider: Is censoring informative? (Related to outcome?)
Exposure / Predictor Definition
For Observational Studies
| Consideration |
Question |
| Binary vs. continuous |
Is exposure yes/no or a dose/level? |
| Timing |
When was exposure measured? Before outcome possible? |
| Duration |
Single point or cumulative? |
| Variability |
Does exposure change over time? |
Avoiding Data Leakage
For prediction models:
- Features must be available at prediction time
- Cannot use information that comes after time-zero
- Cannot use information that requires knowing the outcome
Red flags:
- Using discharge diagnoses to predict at admission
- Using lab values from after the event
- Using length of stay to predict mortality
Outcome Definition
Characteristics of Good Outcomes
| Property |
Description |
| Clinically meaningful |
Matters to patients or clinicians |
| Objective |
Clearly measurable, reproducible |
| Available |
Ascertainable in the data |
| Appropriate timing |
Sufficient follow-up to observe |
Common ICU Outcomes
| Outcome |
Type |
Definition Considerations |
| Mortality |
Binary / Time-to-event |
ICU, hospital, 28-day, 90-day? |
| Length of stay |
Continuous / Time-to-event |
ICU or hospital? Censor deaths? |
| Readmission |
Binary / Time-to-event |
To ICU? To hospital? Time window? |
| AKI |
Binary / Ordinal |
KDIGO stage? Timing relative to exposure? |
| Ventilator-free days |
Count (composite) |
Accounts for death as competing event |
| Organ dysfunction |
Continuous |
SOFA score, specific organ scores |
Competing Events
Some outcomes have competing events:
- Studying ICU discharge → death is competing event
- Studying readmission → death prevents readmission
Options:
- Composite outcome (either event)
- Competing risk analysis (Fine-Gray)
- Cause-specific analysis
Confounding
Identifying Confounders
A confounder is a variable that:
- Is associated with the exposure
- Is associated with the outcome
- Is NOT on the causal pathway between exposure and outcome
Common Confounder Categories in ICU Research
| Category |
Examples |
| Demographics |
Age, sex, race |
| Comorbidities |
Charlson, Elixhauser, specific diseases |
| Acute severity |
APACHE, SOFA, SAPS |
| Admission characteristics |
Admission source, admission type |
| Process measures |
Time of day, day of week |
Adjustment Strategies
| Strategy |
Description |
Assumption |
| Multivariable regression |
Include confounders as covariates |
Correct model specification |
| Propensity score matching |
Match on PS |
Sufficient overlap, balance achieved |
| IPTW |
Weight by inverse PS |
Sufficient overlap, correct PS model |
| Stratification |
Analyze within strata |
Sufficient data per stratum |
Unmeasured Confounding
Problem: Can never prove no unmeasured confounding in observational data.
Mitigation:
- Be explicit about assumed confounders
- Use negative control outcomes
- Quantitative bias analysis (E-value)
- Discuss plausible unmeasured confounders
Sensitivity Analysis Planning
Pre-Specified Sensitivity Analyses
Plan before looking at data:
| Type |
Purpose |
Example |
| Different cohort |
Check robustness to inclusion criteria |
Include vs. exclude missing data |
| Different outcome |
Check outcome definition sensitivity |
28-day vs. hospital mortality |
| Different model |
Check model specification |
Add/remove covariates |
| Different method |
Check analytic approach |
Propensity matching vs. IPTW |
| Subgroup |
Check effect modification |
Stratify by severity |
Bias Quantification
For causal inference:
- E-value: How strong would unmeasured confounding need to be to nullify the result?
- Probabilistic bias analysis: Model uncertainty about bias
Power and Sample Size
Pre-Study Considerations
Before starting, determine:
- Minimum clinically important effect size
- Expected event rate
- Required sample size for adequate power
Rules of Thumb
| Analysis |
Minimum |
| Regression |
10-20 observations per predictor |
| Logistic regression |
10-20 events per predictor |
| Cox regression |
10-20 events per predictor |
| Propensity matching |
Sufficient overlap for matching |
What If Underpowered?
- Acknowledge limitation
- Report effect size and CI (even if non-significant)
- Consider as hypothesis-generating
Reproducibility Checklist
Before finalizing design, ensure:
Common Design Pitfalls
| Pitfall |
Problem |
Fix |
| Vague inclusion criteria |
Unreproducible cohort |
Use explicit codes/thresholds |
| Time-zero after exposure |
Immortal time bias |
Align time-zero with eligibility |
| Outcome available at baseline |
Prevalent vs. incident confusion |
Exclude baseline cases |
| Future information as predictor |
Data leakage |
Restrict to pre-time-zero data |
| Ignoring clustering |
Wrong standard errors |
Model correlation structure |
| Post-hoc subgroups |
Inflated false positive rate |
Pre-specify or label exploratory |
1---2name: study-design-checklist3description: Good analysis starts with good study design. This checklist ensures key design elements are addressed before analysis begins.4---5# Study Design Checklist67## Overview89Good analysis starts with good study design. This checklist ensures key design elements are addressed before analysis begins.1011---1213## Research Question Formulation1415### PICO(T) Framework1617| Component | Question | Example |18|-----------|----------|---------|19| **P**opulation | Who are we studying? | Adult ICU patients with sepsis |20| **I**ntervention/Exposure | What exposure or treatment? | Early vs. late vasopressor initiation |21| **C**omparison | Compared to what? | Standard care, alternative treatment, no exposure |22| **O**utcome | What are we measuring? | 28-day mortality |23| **T**ime | Over what period? | Within first 24 hours of ICU admission |2425### Question Checklist2627- [ ] Is the question clearly stated in plain language?28- [ ] Is it answerable with available data?29- [ ] Is it clinically meaningful?30- [ ] Is it novel or confirmatory of prior work?3132---3334## Cohort Definition3536### Inclusion Criteria3738Define who enters the study:3940| Criterion Type | Examples |41|----------------|----------|42| Diagnosis | Sepsis-3 criteria, ICD codes, clinical definition |43| Setting | ICU admission, specific unit type |44| Age | Adults (≥18), specific range |45| Time | Admission within study period |46| Data quality | Required variables available |4748### Exclusion Criteria4950Define who is removed (with justification):5152| Criterion | Justification |53|-----------|---------------|54| Age <18 | Pediatric physiology differs |55| LOS <24h | Insufficient observation time |56| Readmission | Avoid correlated observations |57| Missing outcome | Cannot assess endpoint |58| Prior exposure | Clean exposure window needed |59| Comfort care only | Different treatment goals |6061### Documentation Requirements6263For each criterion, document:64- Exact definition (codes, thresholds, timing)65- Number excluded at each step66- Justify each exclusion6768**CONSORT-style flow diagram recommended.**6970---7172## Unit of Analysis7374### Options7576| Unit | When to Use | Watch For |77|------|-------------|-----------|78| Patient | One observation per person | Multiple admissions → choose first, last, or random |79| Admission | One observation per hospitalization | Same patient multiple times → clustering |80| ICU stay | One observation per ICU episode | Transfers between units |81| Patient-day | Time-varying exposures | Autocorrelation |8283### Key Decision: Multiple Events per Patient8485If patients can have multiple admissions/stays:8687| Approach | Pros | Cons |88|----------|------|------|89| First only | Simple, independent | Loses data, selection bias |90| Last only | May capture sickest | Selection bias |91| Random one | Unbiased selection | Loses data |92| All (clustered) | Uses all data | Must model clustering |93| Index event (defined criteria) | Clinically meaningful | Requires clear definition |9495---9697## Time-Zero and Follow-Up9899### Time-Zero Definition100101Time-zero is the moment when:102- Follow-up begins103- Patient becomes "at risk" for outcome104- Exposure status should be determined (or treatment assigned)105106| Common Choices | Appropriate When |107|----------------|------------------|108| Hospital admission | Studying hospital-wide exposures |109| ICU admission | ICU-specific questions |110| Diagnosis time | Studying disease course |111| Treatment initiation | Caution: immortal time bias if not universal |112| Fixed landmark (e.g., day 3) | Ensuring minimum exposure time |113114### Follow-Up Period115116- **Start:** Time-zero117- **End:** Outcome, death, discharge, loss to follow-up, or administrative censoring118- **Fixed horizon:** e.g., 30 days, 90 days, hospital stay119120### Censoring121122Define what ends follow-up without outcome:123- Discharge alive124- Transfer to another facility125- End of study period126- Loss of data availability127128**Consider:** Is censoring informative? (Related to outcome?)129130---131132## Exposure / Predictor Definition133134### For Observational Studies135136| Consideration | Question |137|---------------|----------|138| Binary vs. continuous | Is exposure yes/no or a dose/level? |139| Timing | When was exposure measured? Before outcome possible? |140| Duration | Single point or cumulative? |141| Variability | Does exposure change over time? |142143### Avoiding Data Leakage144145For prediction models:146- Features must be available at prediction time147- Cannot use information that comes after time-zero148- Cannot use information that requires knowing the outcome149150**Red flags:**151- Using discharge diagnoses to predict at admission152- Using lab values from after the event153- Using length of stay to predict mortality154155---156157## Outcome Definition158159### Characteristics of Good Outcomes160161| Property | Description |162|----------|-------------|163| Clinically meaningful | Matters to patients or clinicians |164| Objective | Clearly measurable, reproducible |165| Available | Ascertainable in the data |166| Appropriate timing | Sufficient follow-up to observe |167168### Common ICU Outcomes169170| Outcome | Type | Definition Considerations |171|---------|------|---------------------------|172| Mortality | Binary / Time-to-event | ICU, hospital, 28-day, 90-day? |173| Length of stay | Continuous / Time-to-event | ICU or hospital? Censor deaths? |174| Readmission | Binary / Time-to-event | To ICU? To hospital? Time window? |175| AKI | Binary / Ordinal | KDIGO stage? Timing relative to exposure? |176| Ventilator-free days | Count (composite) | Accounts for death as competing event |177| Organ dysfunction | Continuous | SOFA score, specific organ scores |178179### Competing Events180181Some outcomes have competing events:182- Studying ICU discharge → death is competing event183- Studying readmission → death prevents readmission184185Options:186- Composite outcome (either event)187- Competing risk analysis (Fine-Gray)188- Cause-specific analysis189190---191192## Confounding193194### Identifying Confounders195196A confounder is a variable that:1971. Is associated with the exposure1982. Is associated with the outcome1993. Is NOT on the causal pathway between exposure and outcome200201### Common Confounder Categories in ICU Research202203| Category | Examples |204|----------|----------|205| Demographics | Age, sex, race |206| Comorbidities | Charlson, Elixhauser, specific diseases |207| Acute severity | APACHE, SOFA, SAPS |208| Admission characteristics | Admission source, admission type |209| Process measures | Time of day, day of week |210211### Adjustment Strategies212213| Strategy | Description | Assumption |214|----------|-------------|------------|215| Multivariable regression | Include confounders as covariates | Correct model specification |216| Propensity score matching | Match on PS | Sufficient overlap, balance achieved |217| IPTW | Weight by inverse PS | Sufficient overlap, correct PS model |218| Stratification | Analyze within strata | Sufficient data per stratum |219220### Unmeasured Confounding221222**Problem:** Can never prove no unmeasured confounding in observational data.223224**Mitigation:**225- Be explicit about assumed confounders226- Use negative control outcomes227- Quantitative bias analysis (E-value)228- Discuss plausible unmeasured confounders229230---231232## Sensitivity Analysis Planning233234### Pre-Specified Sensitivity Analyses235236Plan before looking at data:237238| Type | Purpose | Example |239|------|---------|---------|240| Different cohort | Check robustness to inclusion criteria | Include vs. exclude missing data |241| Different outcome | Check outcome definition sensitivity | 28-day vs. hospital mortality |242| Different model | Check model specification | Add/remove covariates |243| Different method | Check analytic approach | Propensity matching vs. IPTW |244| Subgroup | Check effect modification | Stratify by severity |245246### Bias Quantification247248For causal inference:249- **E-value:** How strong would unmeasured confounding need to be to nullify the result?250- **Probabilistic bias analysis:** Model uncertainty about bias251252---253254## Power and Sample Size255256### Pre-Study Considerations257258Before starting, determine:259- Minimum clinically important effect size260- Expected event rate261- Required sample size for adequate power262263### Rules of Thumb264265| Analysis | Minimum |266|----------|---------|267| Regression | 10-20 observations per predictor |268| Logistic regression | 10-20 events per predictor |269| Cox regression | 10-20 events per predictor |270| Propensity matching | Sufficient overlap for matching |271272### What If Underpowered?273274- Acknowledge limitation275- Report effect size and CI (even if non-significant)276- Consider as hypothesis-generating277278---279280## Reproducibility Checklist281282Before finalizing design, ensure:283284- [ ] **Research question** is clearly stated (PICO format)285- [ ] **Population** is defined with explicit inclusion/exclusion286- [ ] **Unit of analysis** is specified287- [ ] **Time-zero** is clearly defined288- [ ] **Follow-up** period is specified289- [ ] **Outcome** is objectively defined290- [ ] **Exposure/predictors** are defined and temporally appropriate291- [ ] **Confounders** are identified with adjustment plan292- [ ] **Missing data** handling is planned293- [ ] **Sensitivity analyses** are pre-specified294- [ ] **Sample size** is adequate for planned analyses295296---297298## Common Design Pitfalls299300| Pitfall | Problem | Fix |301|---------|---------|-----|302| Vague inclusion criteria | Unreproducible cohort | Use explicit codes/thresholds |303| Time-zero after exposure | Immortal time bias | Align time-zero with eligibility |304| Outcome available at baseline | Prevalent vs. incident confusion | Exclude baseline cases |305| Future information as predictor | Data leakage | Restrict to pre-time-zero data |306| Ignoring clustering | Wrong standard errors | Model correlation structure |307| Post-hoc subgroups | Inflated false positive rate | Pre-specify or label exploratory |